{
    "nct_id": "NCT03349710",
    "official_title": "A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Participants With Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)",
    "inclusion_criteria": "* Histologically proven squamous cell carcinoma of the head and neck (SCCHN) from one of the following primary sites: oral cavity, oropharynx, hypopharynx, and larynx\n* Locally advanced disease which is unresectable, or resectable but suitable for an organ sparing approach\n* No previous radiotherapy or systemic treatment for SCCHN\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Carcinoma originating in the nasopharynx or paranasal sinus, squamous cell carcinoma that originated from the skin and salivary gland or non-squamous histology (e.g., mucosal melanoma), squamous cell carcinoma of unknown primary\n* Clinical or radiological evidence of metastatic disease\n* Prior radiotherapy that overlaps with radiation fields\n\nOther protocol defined inclusion/exclusion criteria could apply",
    "miscellaneous_criteria": "For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com"
}